Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone.
Poorva M. Nemlekar, MS
Advertisement
Articles by Poorva M. Nemlekar, MS
Advertisement
Latest Updated Articles
Combined Effect of Continuous Glucose Monitoring and Semaglutide: Analysis of Administrative ClaimsPublished: April 3rd 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
2
Revumenib Granted FDA Approval for R/R NPM1-Mutated AML
3
AMCP Nexus Bringing the Latest on Health Policy, Drug Access, and Value-Based Care
4
Low Trial Enrollment, Racial Disparities Limit Breast Cancer Treatment Innovation
5
